Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 30;14(1):12478.
doi: 10.1038/s41598-024-63155-z.

Risk of second primary thyroid cancer in cancer survivors

Yewei Yuan #  1 , Peng Sun #  2 , Hualin Xiao  2 , Lingfan Li  2 , Junyan Li  3 , Xiang Ai  4
Affiliations

Risk of second primary thyroid cancer in cancer survivors

Yewei Yuan et al. Sci Rep. .

Abstract

A risk factor for thyroid cancer (TC) may be a history of former cancer and cancer therapy. The precise risk of a second primary thyroid carcinoma has not yet been revealed. In this study, we evaluated standardized incidence ratios (SIRs) of second primary thyroid cancer (SPTC) with consideration of different conditions and further analyzed the clinicopathological characteristics and survival of these patients. The cohort was selected from the US Surveillance, Epidemiology, and End Results (SEER) Program between 1975 and 2019. The standardized incidence ratios, morbidity risk, clinicopathological features, and survival of second primary thyroid carcinoma were analyzed. Propensity score matching (PSM) was used to balance covariates. Kaplan-Meier method was performed to assess the survival outcomes. Overall, 7066 patients with SPTC and 83,113 patients with primary TC were identified. The SIR of TC in tumor patients was 1.51/10,000, statistically higher than the natural population (0.94/10,000, P < 0.05). The most significant tumors contributing to the increased SIRs of SPTC were acute lymphocytic leukemia (3.49/10,000), Hodgkin's lymphoma-nodal (3.29/10,000), salivary gland cancer (3.23/10,000), and kidney and renal pelvis cancer (3.05/10,000). The incidence of TC increased significantly in tumor patients who received radiotherapy/chemotherapy before age 35. The age at diagnosis of the SPTC was much older than the primary TC (64.01 vs. 49.55 years, p < 0.001). The SPTC had a higher percentage of histological grades 3/4 (23.14% vs. 15.19%, p < 0.001). Survival analyses demonstrated a worse prognosis for the SPTC group compared to the primary TC group. But after PSM, the survival outcomes of the two groups tended to be equivalent (P = 0.584). The SIRs of TC are higher in tumor patients. The most significant factors contributing to the increased risk of SPTC were some specific former tumors and acceptance of radiotherapy/ chemotherapy before age 35. There was no significant difference in survival between SPTC and primary TC.

Keywords: Risk; SEER database; Second primary thyroid cancer; Standardized incidence ratios; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
SIRs of second primary TC according to age at diagnosis and radiotherapy/chemotherapy of former tumor. (a) The incidence of TC increased in patients who received chemotherapy before the age of 35 years. (b) The incidence of TC increased in patients who received radiotherapy before the age of 35 years.
Figure 2
Figure 2
The analysis of thyroid cancer-specific survival curves of the primary TC and the secondary TC. (a) TCSS curves before PSM. (b) TCSS curves after PSM.
See this image and copyright information in PMC

References

    1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–1348. doi: 10.1001/jama.2017.2719. - DOI - PMC - PubMed
    1. Vaccarella S, Lortet-Tieulent J, Colombet M, Davies L, Stiller CA, Schüz J, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: A population-based study. Lancet Diabetes Endocrinol. 2021;9:144–152. doi: 10.1016/s2213-8587(20)30401-0. - DOI - PubMed
    1. Hussein M, Mueller L, Issa PP, Haidari M, Trinh L, Toraih E, et al. Latency trend analysis as a guide to screening malignancy survivors for second primary thyroid cancer. Biomedicines. 2022 doi: 10.3390/biomedicines10081984. - DOI - PMC - PubMed
    1. Schonfeld SJ, Morton LM, Berrington de González A, Curtis RE, Kitahara CM. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000–2015. Cancer Epidemiol. 2020;64:101664. doi: 10.1016/j.canep.2019.101664. - DOI - PMC - PubMed
    1. Piek MW, de Boer JP, van Duijnhoven F, van der Wal JE, Vriens M, van Leeuwaarde RS, et al. The co-occurrence of both breast- and differentiated thyroid cancer: Incidence, association and clinical implications for daily practice. BMC Cancer. 2022;22:1018. doi: 10.1186/s12885-022-10069-6. - DOI - PMC - PubMed